Jiangsu Yunyang Group Pharmaceutical Co.,Ltd.
As of 20 November 2026, for the company name Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. as recorded, 1 application with this name as first applicant is listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 6 records, across 4 drug names; since 24 August 2026, the records list Accepted: 1 application; the chemical-drug catalogue lists 2 active records with this name as holder; 19 active API registrations list this name as first registered company; 18 further acceptance records name it after the first applicant.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.
Drug filings
6 acceptance records as first applicant, grouped into 4 source drug names. Source data as of 2026/11/20.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
愈美片 · No verified English name 1 records · Latest accepted 2026/09/24
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601810 | Supplement | 2026/09/24 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Arginine and Ibuprofen Granules 3 records · Latest accepted 2025/05/16
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2500987 | Supplement | 2025/05/16 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHB2500985 | Supplement | 2025/05/16 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| CYHB2500983 | Supplement | 2025/05/16 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution 1 records · Latest accepted 2025/05/11
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2500944 | Supplement | 2025/05/11 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Bromhexine Hydrochloride Tablets 1 records · Latest accepted 2025/02/22
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550124 | Supplement | 2025/02/22 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Changes in the last 90 days
1 events from 2026/08/24 to 2026/11/21. CDE data as of 2026/11/20; NMPA data as of 2026/11/20.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Accepted: 1 application
- 2026/09/24Accepted
愈美片 · No verified English name
CYHB2601810
Fact date: 2026/09/24 · Date added to this site: 2026/10/21
View source ↗
Under review
1 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| 愈美片 · No verified English name | CYHB2601810 | Supplement | 2026/09/24 | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
Catalogue holder records
2 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | NMPA approval no. | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Bromhexine Hydrochloride Tablets | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H32023255 | 2026/03/31 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Clozapine Tablets | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | 国药准字H32023357 | 2020/09/04 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
19 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 甲基橙皮苷 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20240000596 | I | 2025/05/23 | CDE ↗ |
| 盐酸甲氧氯普胺 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20230000627 | A | 2025/04/30 | CDE ↗ |
| 布美他尼 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20230000614 | A | 2024/11/07 | CDE ↗ |
| 硝唑尼特 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20220001112 | I | 2023/01/10 | CDE ↗ |
| 吗啉硝唑 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20220000877 | A | 2024/11/19 | CDE ↗ |
| 精氨酸布洛芬 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20220001054 | A | 2024/03/15 | CDE ↗ |
| 醋酸阿比特龙 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20210000347 | A | 2022/10/25 | CDE ↗ |
| 依普利酮 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20200001280 | A | 2023/08/11 | CDE ↗ |
| 利伐沙班 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20200000353 | A | 2025/12/24 | CDE ↗ |
| 阿哌沙班 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190000972 | I | 2019/11/05 | CDE ↗ |
| 左奥硝唑 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190021363 | A | 2023/10/30 | CDE ↗ |
| 硝酸咪康唑 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190006908 | A | 2023/03/24 | CDE ↗ |
| 盐酸普萘洛尔 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190004980 | A | 2025/08/23 | CDE ↗ |
| 盐酸可乐定 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190004979 | A | 2025/08/05 | CDE ↗ |
| 氯氮平 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190004972 | A | 2025/07/18 | CDE ↗ |
| 美洛昔康 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190004969 | A | 2025/08/05 | CDE ↗ |
| 克霉唑 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190004934 | A | 2026/03/13 | CDE ↗ |
| 盐酸普罗帕酮 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20190004933 | A | 2025/08/30 | CDE ↗ |
| 盐酸莫西沙星 · No verified English name | Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | Y20170000704 | I | — | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
18 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Ursodeoxycholic acid oral suspension | CYHB2502344 | Supplement | 2025/11/13 | 成都赛璟生物医药科技有限公司; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Levothyroxine Sodium Tablets | CYHS2503787 | Generic | 2025/10/24 | Hai Hong Heng Long (Hainan) Bio Technology Co., Ltd. romanized; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Levothyroxine Sodium Tablets | CYHS2503786 | Generic | 2025/10/24 | Hai Hong Heng Long (Hainan) Bio Technology Co., Ltd. romanized; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Furosemide Tablets | CYHS2503564 | Generic | 2025/09/29 | Hai Hong Heng Long (Hainan) Bio Technology Co., Ltd. romanized; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Ursodeoxycholic acid oral suspension | CYHS2302006 | Generic | 2023/07/27 | 成都赛璟生物医药科技有限公司; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Arginine and Ibuprofen Granules | CYHS2301222 | Generic | 2023/05/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Arginine and Ibuprofen Granules | CYHS2301221 | Generic | 2023/05/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Arginine and Ibuprofen Granules | CYHS2301220 | Generic | 2023/05/06 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Ambroxol Hydrochloride Oral Solution | CYHS2300569 | Generic | 2023/02/18 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution | CYHS2300568 | Generic | 2023/02/18 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Rivaroxaban Tablets | CYHB2201884 | Supplement | 2022/10/14 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Macitentan Tablets | CYHS2201679 | Generic | 2022/10/10 | Nanjing Ze Heng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Eplerenone Tablets | CYHS2102151 | Generic | 2021/12/17 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Eplerenone Tablets | CYHS2102150 | Generic | 2021/12/17 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Abiraterone Acetate Tablets | CYHS2101758 | Generic | 2021/09/23 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Rivaroxaban Tablets | CYHS2101095 | Generic | 2021/04/23 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Rivaroxaban Tablets | CYHS2101094 | Generic | 2021/04/23 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
| Rivaroxaban Tablets | CYHS2100015 | Generic | 2021/01/08 | Nanjing Cavendish Bio-engineering Technology Co., Ltd.; Jiangsu Yunyang Group Pharmaceutical Co.,Ltd. | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/20
- Chemical-drug catalogue
- Last successful update: 2026/11/20
- API registrations
- Last successful update: 2026/11/20
- NMPA drug delivery notices
- Last successful update: 2026/11/20
Loaded notices dated 2026-11-06 to 2026-11-20; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.